Background: Methotrexate (MTX) is an effective and safe drug in the treatment of juvenile idiopathic arthritis (JIA). Despite its safety, MTX-related gastrointestinal adverse effects before and after MTX administration, termed MTX intolerance, occur frequently, leading to non-compliance and potentially premature MTX termination. The aim of this study was to construct a risk model to predict MTX intolerance. Methods: In a prospective JIA cohort, clinical variables and single nucleotide polymorphisms were determined at MTX start. The Methotrexate Intolerance Severity Score was employed to measure MTX intolerance in the first year of treatment. MTX intolerance was most prevalent at 6 or 12 months after MTX start, which was defined as the outco...
Background: Methotrexate (MTX) therapy has proven to be a successful and safe treatment for Juvenile...
Objectives. To determine predictors for response to treatment with methotrexate in juvenile idiopath...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
textabstractBackground: Methotrexate (MTX) is an effective and safe drug in the treatment of juvenil...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JI...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JIA...
OBJECTIVE: To design and validate a new questionnaire for identifying patients with methotrexate (MT...
OBJECTIVE: To design and validate a new questionnaire for identifying patients with methotrexate (MT...
Methotrexate (MTX) is the cornerstone treatment in juvenile idiopathic arthritis (JIA). Nevertheless...
OBJECTIVES: To determine whether baseline demographic, clinical, articular and laboratory variables ...
Objectives To determine whether baseline demographic, clinical, articular and laboratory variables p...
Methotrexate that has a safe and inexpensive profile is a first choice of juvenile idiopathic arthri...
To determine whether demographic, clinical, and laboratory variables measurable at baseline predict ...
Introduction: The aim of this study was to determine the prevalence of gastrointestinal and behaviou...
Objectives: The study aimed to determine the factors that increase the risk of disease flare in pati...
Background: Methotrexate (MTX) therapy has proven to be a successful and safe treatment for Juvenile...
Objectives. To determine predictors for response to treatment with methotrexate in juvenile idiopath...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...
textabstractBackground: Methotrexate (MTX) is an effective and safe drug in the treatment of juvenil...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JI...
Objectives Methotrexate (MTX) is a cheap and effi cacious drug in juvenile idiopathic arthritis (JIA...
OBJECTIVE: To design and validate a new questionnaire for identifying patients with methotrexate (MT...
OBJECTIVE: To design and validate a new questionnaire for identifying patients with methotrexate (MT...
Methotrexate (MTX) is the cornerstone treatment in juvenile idiopathic arthritis (JIA). Nevertheless...
OBJECTIVES: To determine whether baseline demographic, clinical, articular and laboratory variables ...
Objectives To determine whether baseline demographic, clinical, articular and laboratory variables p...
Methotrexate that has a safe and inexpensive profile is a first choice of juvenile idiopathic arthri...
To determine whether demographic, clinical, and laboratory variables measurable at baseline predict ...
Introduction: The aim of this study was to determine the prevalence of gastrointestinal and behaviou...
Objectives: The study aimed to determine the factors that increase the risk of disease flare in pati...
Background: Methotrexate (MTX) therapy has proven to be a successful and safe treatment for Juvenile...
Objectives. To determine predictors for response to treatment with methotrexate in juvenile idiopath...
Purpose: Methotrexate (MTX) is the first choice conventional disease-modifying antirheumatic drug (D...